235 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (89)
- Autoimmune Disorders (1)
- Blood Disorders (3)
- Bone & Muscle (1)
- Cancer (18)
- COVID-19 (Coronavirus) (4)
- Diabetes (2)
- Endocrine & Metabolic Disease (3)
- Hair and Skin Disorders (1)
- Healthy Volunteers (12)
- Heart Disease (17)
- Kidney Disease (1)
- (-) Liver Disease (2)
- Lung Disease (2)
- Neurological Disorders (3)
- Nutrition (2)
- Obesity (2)
- Obstetrics & Gynecology (3)
- Pediatrics (7)
- Surgery (2)
- Transplant (3)
Displaying 1 - 4 of 4
Condition: Liver Disease
Investigator: Joshua Cook, MD, PhD
Status: Currently Recruiting
We are conducting a research study on the effect of high insulin levels on the buildup of excessive liver fat ("fatty liver disease") in people at risk for type 2 diabetes. We are seeking adult volunteers, ages 18-65, who have obesity with a body mass index of 30-45, and have been diagnosed with, or are at risk for,…
Condition: Cancer / Gynecologic Cancer
Investigator: June Hou, MD
Status: Closed
The purpose of this research study is to test the safety and determine the highest tolerable dose of SL-172154 (study drug) that can be given with Pegylated Liposomal Doxorubicin (PLD) or Mirvetuximab Soravtansine (MIRV). Another purpose of this study is to understand if SL-127154 and PLD or MIRV is effective in managing…
Condition: Liver Disease
Investigator: Carl Bazil, MD, PhD
Status: Closed
The main purpose of this research study is to investigate the effectiveness of avatrombopag (the study drug under investigation) in increasing the amount of platelets (a type of cell found in the blood) in patients with chronic liver disease who need to have an elective procedure but have thrombocytopenia (low platelet counts…
Condition: Cancer / Gynecologic Cancer
Investigator: Jason Wright, MD
Status: Closed
XMT-1536 (upifitamab rilsodotin) is a targeted therapy, which means that it is directed specifically at a tumor. It is a type of antibody-drug conjugate; this means it has 2 parts that are joined together into one drug. The first part is an antibody that binds to NaPi2b (sodium-dependent phosphate transporter), a protein on the surface of the cells of your…